High volume hydration Mg- | High volume hydration Mg+ | Low volume hydration Mg+ | |
---|---|---|---|
(n = 41) | (n = 27) | (n = 17) | |
Age (year) | 66 (63 to 70) | 66 (57 to 70) | 63 (62 to 67) |
Gender Male (%) | 31 (75.6) | 18 (66.6) | 16 (94.1) |
BSA (m2) | 1.7 ± 0.2 | 1.6 ± 0.2 | 1.7 ± 0.2 |
PS (ECOG): 0 (%) | 5 (12.1) | 4 (14.8) | 5 (29.4) |
1 (%) | 36 (87.8) | 23 (85.2) | 12 (70.6) |
Stage I (%) | 0 (0) | 1 (3.7) | 0 (0) |
II (%) | 5 (12.2) | 3 (11.1) | 3 (17.6) |
III (%) | 25 (61.0) | 15 (55.5) | 8 (47.1) |
IV (%) | 9 (22.0) | 7 (25.9) | 6 (35.3) |
Others (%) | 2 (4.9) | 1 (3.7) | 0 (0) |
Histology Adenocarcinoma (%) | 17 (41.5) | 13 (48.1) | 11 (64.7) |
Squamous cell carcinoma (%) | 11 (26.8) | 7 (25.9) | 5 (29.4) |
Small cell carcinoma (%) | 9 (22.0) | 6 (22.2) | 1 (5.9) |
Others (%) | 4 (9.8) | 1 (3.7) | 0 (0) |
Serum Hb (g/dl) | 13.3 (12.0 to 14.8) | 13.6 (12.8 to 14.8) | 13.3 (12.7 to 14.9) |
Serum Alb (g/dl) | 4.0 ± 0.4 | 4.1 ± 0.4 | 3.9 ± 0.4 |
Cisplatin dose (mg/m2) | 80 (80 to 80) | 80 (75 to 80) | 80 (75 to 80) |
Regular use drug | |||
NSAIDs (%) | 10 (24.4) | 2 (7.4) | 2 (11.7) |
Mg for purgative (%) | 14 (34.1) | 8 (29.6) | 5 (29.4) |
Combined anticancer agent (%) | |||
VNB | 22 (53.7) | 13 (48.1) | 10 (58.8) |
PEM | 3 (7.3) | 6 (22.2) | 5 (29.4) |
CPT-11 | 3 (7.4) | 1 (3.7) | 0 |
VP-16 | 8 (19.5) | 6 (22.2) | 1 (5.9) |
GEM | 2 (4.9) | 0 | 1 (5.9) |
S-1 | 1 (2.4) | 1 (3.7) | 0 |
AMR | 1 (2.4) | 0 | 0 |
DTX | 1 (2.4) | 0 | 0 |